Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,859 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05494190Recruiting
Treatment strategy for lymph node spread in hypopharyngeal cancer
This trial studies treatment choices for people with hypopharyngeal squamous cell cancer that has spread to certain neck lymph nodes. The goal is to help control the cancer in the neck and improve outcomes when the lymph node area can be surgically managed.
Harbin, HeilongjiangAges 18–75 - NCT05495152RecruitingPhase 3
Sintilimab after esophageal surgery to help prevent cancer return
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
Zhengzhou, HenanAges 18–70 - NCT05498064Recruiting
Study of ensartinib for advanced ALK-positive lung cancer
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05502198Recruiting
How muscle loss matters in advanced liver disease
This study looks at how loss of muscle strength or mass (sarcopenia) relates to advanced liver disease. It may help doctors understand which patients are at higher risk and could guide future care choices.
EksjöAges 18 years+ - NCT05523245Recruiting
AI MRI test to predict treatment response in rectal cancer
This study uses an AI computer program to read special MRI images and predict how well treatment (given before surgery) will work for people with locally advanced rectal cancer. It may help doctors better plan who benefits most from neoadjuvant therapy (treatment before surgery).
Guangzhou, GuangdongAges 18 years+ - NCT05527470RecruitingPhase 3
Chemo then radiation for newly diagnosed advanced nasopharyngeal cancer
This Phase 3 trial tests giving chemotherapy first, then either radiation alone or chemotherapy together with radiation. It aims to improve treatment control for people with newly diagnosed, advanced nasopharyngeal cancer.
Guilin, GuangxiAges 18–65 - NCT05537922Recruiting
Study uses data to tailor lung cancer care with immunotherapy
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
Chicago, IllinoisAges 18 years+ - NCT05539196Recruiting
Registry for Exablate treatment in Parkinson’s with medication problems
This trial is a real-world registry that follows people with Parkinson’s who are planning to get an Exablate 4000 procedure (a focused ultrasound treatment) for one-sided symptoms that are difficult to control with medication. It mainly checks outcomes and safety over time, helping doctors understand how well this treatment works in everyday care.
Baltimore, MarylandAges 30–99 - NCT05547607Recruiting
Study of heart valve infection signs on heart scans
This study looks at clinical symptoms and test findings to better understand heart valve infection (endocarditis) in adults. It may help doctors recognize the condition sooner and interpret echocardiography results more accurately.
Cona, FerraraAges 18 years+ - NCT05554276RecruitingPhase 2
PD-1 immunotherapy, chemotherapy, and radiation for advanced cervical cancer
This trial tests whether chemotherapy plus an immune treatment called PD-1, along with radiation, can help people with cervical cancer that cannot be removed with surgery. It’s aimed at locally advanced, unresectable cervical squamous cell cancer.
ShanghaiAges 18–70 - NCT05559645Recruiting
Oral drug trial for EGFR-mutated lung cancer after prior treatment
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05563467RecruitingPhase 2
Pembrolizumab for advanced adrenocortical cancer that keeps growing
This Phase 2 trial studies pembrolizumab (an immune therapy) in people with advanced adrenocortical carcinoma that has progressed despite prior chemotherapy. It aims to shrink tumors or slow growth by helping the immune system recognize the cancer.
Gliwice, Silesian VoivodeshipAges 18 years+ - NCT05564091Recruiting
Add a minimally invasive canaloplasty step to cataract surgery
This trial compares standard cataract surgery alone versus cataract surgery plus a procedure to improve fluid drainage in the eye. It is intended for people with mild to moderate open-angle glaucoma, to see if adding this step helps control eye pressure and preserve vision.
Sugar Land, TexasAges 55 years+ - NCT05570253RecruitingPhase 2
SDX-7320 plus eribulin for metastatic triple-negative breast cancer
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
Miami, FloridaAges 18 years+ - NCT05571644RecruitingPhase 2
Study compares two pre-surgery treatments for locally advanced rectal cancer
This Phase 2 trial tests whether a newer combination chemotherapy plus an immunotherapy medicine (cadonilimab/AK104) works better than standard chemotherapy before surgery for locally advanced colorectal cancer. The goal is to shrink the tumor and improve how well treatment works after surgery.
Guangzhou, GuangdongAges 18–70 - NCT05578053Recruiting
Dalpiciclib for hormone receptor–positive advanced breast cancer
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
Shijiazhuang, HebeiAges 18 years+ - NCT05580666RecruitingPhase 3
Lower death risk by adding azithromycin to HIV treatment
This Phase 3 study tests whether adding azithromycin helps people with advanced HIV disease live longer. You would start (or restart or adjust) HIV treatment within 4 weeks and may also receive azithromycin or a comparison approach to see if outcomes improve.
AbidjanAges 18 years+ - NCT05584761RecruitingPhase 1/Phase 2
Cord blood stem cells plus azacitidine for advanced blood cancers
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
Nanjing, JiangsuAges 18–80 - NCT05589818RecruitingPhase 2
Pembrolizumab for advanced lung cancer without key gene targets
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
New York, New YorkAges 18 years+ - NCT05600127RecruitingPhase 2
Chemotherapy then immunotherapy plus surgery for advanced bladder cancer
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
Nijmegen, GelderlandAges 18 years+ - NCT05601726RecruitingPhase 1/Phase 2
Study of a new drug for hard-to-treat AML or high-risk MDS
This early study tests a new medicine (ABD-3001) to see if it’s safe and tolerable, how the body handles it, and whether it shows early signs of helping people with relapsed or hard-to-treat AML or high-risk MDS. It may be an option if standard treatments have already failed and you can’t receive a stem cell transplant.
Marseille, FranceAges 18 years+ - NCT05601440RecruitingPhase 2
Trial for metastatic breast cancer that resisted CDK4/6 treatment
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
Calgary, AlbertaAges Any age - NCT05608200RecruitingPhase 3
Lenvatinib plus immunotherapy with TACE versus standard TACE
This study compares a stronger treatment plan (lenvatinib plus sintilimab plus TACE) against a standard plan (lenvatinib plus TACE) for advanced liver cancer. It aims to see which plan works better to control tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75 - NCT05610501Recruiting
Ultrasound-guided biopsy for pelvic masses
This study looks at how well an ultrasound-guided needle biopsy (Tru-Cut) can safely collect tissue samples from pelvic masses. It may help doctors confirm diagnoses and guide treatment by improving how biopsies are done in real-world care.
LeuvenAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,859 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.